Multiple Sclerosis Drugs - Mexico

Mexico

The Multiple Sclerosis Drugs market in Mexico is anticipated to achieve a revenue of €124.80m in 2024.
With a projected annual growth rate (CAGR 2024-2029) of 1.11%, the market volume is expected to reach €131.90m by 2029.
When compared globally, United States is forecasted to generate the highest revenue of €10,910.00m in 2024.
The demand for multiple sclerosis drugs in Mexico is rapidly increasing due to the rising prevalence of the disease in the country.

Key regions: France, India, United Kingdom, South Korea, Japan

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Multiple Sclerosis Drugs market in Mexico has been experiencing significant growth in recent years.

Customer preferences: Patients suffering from Multiple Sclerosis (MS) in Mexico are increasingly seeking out new treatment options that offer better efficacy and fewer side effects. This has led to a growing demand for innovative drugs that can help manage the symptoms of the disease and improve the quality of life for patients.

Trends in the market: One of the key trends in the Multiple Sclerosis Drugs market in Mexico is the increasing availability of novel therapies that target the underlying causes of the disease. These drugs offer significant advantages over traditional treatments, which focus primarily on symptom management. As a result, they are becoming increasingly popular among patients and healthcare providers alike.Another important trend in the market is the growing use of combination therapies, which involve the use of multiple drugs to achieve better results. This approach has been shown to be particularly effective in managing the symptoms of MS and improving patient outcomes.

Local special circumstances: One of the unique challenges facing the Multiple Sclerosis Drugs market in Mexico is the relatively low level of awareness about the disease among the general population. This has led to delays in diagnosis and treatment, which can have a significant impact on patient outcomes.Another important factor is the high cost of MS drugs, which can be a barrier to access for many patients. This has led to the development of innovative pricing models, such as pay-for-performance and risk-sharing agreements, which aim to make these drugs more affordable and accessible to patients.

Underlying macroeconomic factors: The growth of the Multiple Sclerosis Drugs market in Mexico is being driven by a number of underlying macroeconomic factors, including the country's rapidly aging population and the increasing prevalence of chronic diseases. In addition, the government has been investing heavily in healthcare infrastructure and services, which has helped to improve access to care for patients with MS.Overall, the Multiple Sclerosis Drugs market in Mexico is expected to continue to grow in the coming years, driven by increasing demand for innovative therapies and a growing focus on improving patient outcomes. However, there are also a number of challenges that must be addressed, including the need to raise awareness about the disease and improve access to care for patients.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.